Psychedelic vs Small Molecule — Neurology Deal Terms Comparison
Market Analysis
In neurology, Psychedelic and Small Molecule represent two of the most actively transacted modalities. At Phase 2, Psychedelic deals carry a median total deal value of $3.3B with $378M upfront, compared to $3.0B total value and $343M upfront for Small Molecule. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. Psychedelic development milestones average $978M versus $890M for Small Molecule. Commercial milestones are $919M for Psychedelic and $836M for Small Molecule. Royalty rates range from 12.7%-20.3% for Psychedelic and 12.4%-19.8% for Small Molecule.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do Psychedelic and Small Molecule deal terms compare in neurology?
Which modality commands higher royalty rates: Psychedelic or Small Molecule?
How do milestone structures differ between Psychedelic and Small Molecule?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.